Background: Approximately one-third of all borderline ovarian tumours (BOT) are diagnosed in patients with childbearing potential. Detailed information regarding their specific characteristics and prognostic factors is limited.
Federation of Gynecology and Obstetrics (FIGO) stage and fertility-sparing approach as independent prognostic factors negatively affecting progression-free survival (PFS) while, for patients ≥40 years, higher FIGO stage and incomplete staging was associated with impaired PFS.
Conclusions: Despite favourable survival, young BOT patients with child-bearing potential are at higher risk for disease recurrence. However, relapses usually remain BOT in the preserved ovaries as opposed to older patients being at higher risk for malignant transformation in peritoneal or distant localisation. Therefore, fertility-sparing approach can be justified for younger patients after thorough consultation. Key words: borderline ovarian tumour, surgical treatment, fertility preservation, recurrence, malignant transformation introduction Borderline ovarian tumours (BOT) represent a distinct tumour entity of epithelial origin accounting for approximately 10%-20% of all ovarian neoplasms [1, 2] . In contrast to ovarian cancer, they are characterised by the absence of destructive stromal invasion. They are distinct by an epidemiological shift towards younger women and an excellent overall prognosis with a 5-year survival rate of more than 90% across all tumour stages [3] [4] [5] . Nevertheless, BOT may recur even after more than 10 years and undergo malignant transformation in selected cases [6] .
Since approximately one-third of BOT patients is younger than 40 years and the incidence of BOT has been rising over the past decades, fertility-preserving aspects have become a considerable issue when the treatment plan is defined [7, 8] . Besides higher International Federation of Gynecology and Obstetrics (FIGO) stage, incomplete surgical staging and residual tumour, fertility preservation was recently confirmed to be an independent prognostic factor for disease recurrence in the large cohort study on BOT of the Arbeitsgemeinschaft Gynaekologische Onkologie [(AGO) ROBOT study] [9] . With respect to the excellent overall prognosis, the risk of malignant transformation in case of relapse needs to be carefully investigated. We therefore carried out a focused analysis of the AGO cohort study [9] to reveal potential age-specific differences of treatment and clinical course of BOT patients. A special focus was put on patients in reproductive age to generate a possible base for treatment recommendations in this specific subgroup. methods patients All consecutive patients with primary diagnosis of BOT in the 11-year period between 1998 and 2008 from 24 participating member institutions of the AGO study group were included in this recently published multicentre study (AGO ROBOT study) [9] . Patient cases eligible for study participation at each centre were retrospectively identified by local investigators. Clinical data were then retrieved from hospital records and/or clinical tumour registries. Patients without available paraffin-embedded material or with coincident invasive cancer were excluded. The prospective part of this study included an active follow-up and an independent central pathology review by one of the two specialised gynaeco-pathologists (FK and SH) strictly following current World Health Organisation diagnostic criteria [10] . In case of discrepancies with initial diagnosis, the primary pathologist at the participating centre was contacted, the diagnosis was discussed and consented. Only confirmed cases with BOT were included in the present analysis.
Therapeutic strategies were documented according to patients' charts and surgery reports and aligned with pathology reports. Staging quality was considered comprehensive following German guidelines [11] . This includes bilateral salpingo-oophorectomy in patients ≥55 years or younger patients without attempted organ preservation, omentectomy or omental biopsy, peritoneal biopsies, peritoneal cytology and, for cases with mucinous histology, appendectomy. Neither removal of the uterus nor lymphadenectomy were regarded necessary parts of staging procedures. Fertility-sparing surgery was assumed in patients who were younger than 55 years at diagnosis, and had the uterus and at least parts of one ovary left after operation. For patients with fertility preservation, surgical staging was considered comprehensive when, apart from the reproductive organs, the same surgical steps as described above were carried out. The study protocol was approved by local ethics committees at each participating centre, and written informed consent was obtained from all patients to access their tissue and review their medical records.
statistical analysis
All statistical analyses were conducted using IBM® SPSS® Statistics 19 and R 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). P values of <0.05 were considered statistically significant.
Age-dependent differences regarding clinical characteristics and outcome were evaluated separately for patients <40 and ≥40 years according to the cut-off for primary ovarian insufficiency [12] to put a special focus on patients in reproductive age. Both groups were compared regarding clinicopathological variables and treatment parameters by applying Student's t-test or χ 2 test, as appropriate. Unless otherwise specified, surgical parameters are provided taken together primary and a possible secondary re-staging procedure. Kaplan-Meier method and log-rank test were used to analyse and illustrate progression-free (PFS) and disease-specific overall survival (DSS). For multivariate analysis regarding PFS, Cox regression models were calculated and then presented via forest plots. These models were applied separately for the whole patient cohort as well as for patients <40 and ≥40 years only.
results
A total of 950 patients met the inclusion criteria with confirmed diagnosis of BOT in central pathological review. versus 12.1%, P < 0.001) with comparable distribution of invasive versus non-invasive implants in both age groups (Table 1) . Regarding the primary surgical approach, patients <40 years were more likely to undergo primary laparoscopy compared with patients ≥40 years (43.9% versus 26.0%, P < 0.001, Table 2 , supplementary Figure S1 , available at Annals of Oncology online). A fertility-sparing approach was conducted in 168 of all 950 patients (17.7%), and in 149 of the 280 patients <40 years (53.2%). Therefore, surgical procedures affecting fertility such as hysterectomy (26.8% versus 87.2%, P < 0.001) and bilateral salpingo-oophorectomy (31.1% versus 92.7%, P < 0.001) were significantly less frequent in younger patients compared with patients ≥40 years. Consequently, an inverse distribution of fertility-preserving procedures like unilateral salpingo-oophorectomy (57.5% versus 5.7%, P < 0.001) as well as unilateral or bilateral ovarian cystectomy (37.5% versus 2.8%, P < 0.001) was seen in younger patients as opposed to patients 40 years and older. In general, preservation of a primarily affected ovary after completed surgical treatment was seen in 43 of 168 cases with a fertility-sparing approach (25.6%) sub-dividing into 32 of the 149 patients <40 years (21.5%) and 11 of the 19 patients ≥40 years (57.8%, Table 2 , supplementary Figure S1 , available at Annals of Oncology online).
Further surgical interventions were equally distributed between the two subgroups except for a higher rate of peritoneal biopsies in younger patients (70.0% versus 61.6%, P = 0.01). Significantly more patients <40 years underwent re-staging procedures following incomplete primary surgery (48.6% versus 27.3%, P < 0.001) with the consequence of upstaging in 13.2% versus 8.7% (Table 2 , supplementary Figure S1 , available at Annals of Oncology online). However, surgical outcome in terms of complete cyto-reduction (91.8% versus 92.5%, P = 0.80) and adequate surgical staging (39.6% versus 41.6%, P = 0.57) did not differ between the two age groups ( Table 2 , supplementary Figure S1 , available at Annals of Oncology online).
Of all 950 patients, 74 (7.8%) experienced recurrent disease (Table 3) . Among cases with tumour relapse, invasive carcinoma was detected in 22 of these 74 cases (29.7%) with a rate of 22.4% for serous, 60.0% for mucinous and 50% for endometroid relapse. While the recurrence rate was significantly higher in the younger patient cohort (17.9% versus 3.6%, P < 0.001; 19.0% versus 10.1% 5-year recurrence rate, P < 0.001), malignant transformation was significantly less often observed compared with patients ≥40 years (6 of 50, 12.0% versus 16 of 24, 66.7%, P < 0.001; Table 3 ).
In the younger patient subgroup, almost two thirds of all relapses were diagnosed in remaining ovarian tissue without any case of malignant transformation, while this localisation was significantly less frequent in patients ≥40 years (64% versus 12.5% of patients with recurrent disease, P < 0.001). Contrarily, recurrent disease in peritoneal implants or distant localisation was more frequent among older patients compared with younger patients (87.5% versus 36.0%, P < 0.001) with a significantly higher rate of malignant histology in these cases (71.4% versus 33.3%, P < 0.001). Focusing on 11 patients <40 years who experienced recurrent disease following organ-preserving approach (11 of 32, 34.4%), BOT recurrence was diagnosed in the remaining ipsilateral ovary in four and in the contralateral ovary in seven patients. Initial histologic subtypes did not significantly differ between the two age groups for patients diagnosed with malignant transformation. Of note, in 9 of all 22 patients with Table 3 ). As a consequence of the described results, rates for PFS were significantly lower in patients <40 years (5-year PFS rate 81.0% versus 89.9% in patients ≥40 years, P < 0.001; Table 3 , supplementary Figure S2A , available at Annals of Oncology online) while DSS as assessed by the local investigators did not significantly differ between the two age groups (5-year DSS rate 98.9% versus 97.7%, P = 0.12; Table 3 , supplementary Figure S2B , available at Annals of Oncology online). In multivariate analyses ( Figure 1A-C ) , higher FIGO stage [IIA-C versus IA/B hazard ratio (HR) 2.80, 95% confidence interval (CI) 1.56-5.01; IIIA-C versus IA/B HR 3.38, 95% CI 1.91-5.98], postoperative residual tumour (HR 2.59, 95% CI 1.09-6.19), incomplete staging (HR 2.27, 95% CI 1.44-3.57) and fertility preservation (HR 2.15, 95% CI 1.25-3.70) could be confirmed as independent prognostic factors for unfavourable PFS in the overall cohort (n = 950) ( Figure 1A) .
Focussing on the patient cohort <40 years, higher FIGO stage (IIA-C versus IA/B HR 3.00, 95% CI 1.39-6.48; IIIA-C versus Figure 1B) while, for the patients ≥40 years, only staging quality was an independent prognostic factor (HR 0.36, 95% CI 0.18-0.70; Figure 1C ).
discussion
With this subgroup analysis of the AGO ROBOT study, we could observe that BOT patients with child-bearing potential and fertility-sparing management have a higher risk for disease recurrence in the remaining ovarian tissue. The risk for malignant transformation is however lower than in older patients resulting in an oncologic outcome comparable with the overall cohort. Patients <40 years represent about one-third of all patients in the large cohort of the AGO ROBOT study and were characterised by significantly higher FIGO stage and more peritoneal implants at first diagnosis compared with older patients. In contrast to ovarian cancer where fertility preservation is only reserved for special constellations, conservative surgical treatment represents an important option for patients with BOT [13] . In our cohort, fertility-sparing strategy was followed in more than half of the patients <40 years with preservation of parts of a BOT-affected ovary in 20% of these cases. Surgical outcome in terms of postoperative residual tumour and staging quality did not differ between the age groups. The individual extent of 'adequate' staging procedures might, however, be different in both age groups as more younger patients underwent re-staging surgery when the diagnosis of BOT had already been confirmed. This could have led to more rigorous staging in these cases potentially explaining the higher FIGO stage and the higher rates of up-staging following re-staging procedures in this younger patient cohort.
Overall, an almost threefold higher risk of recurrence without significant impact on overall survival has been previously described [6, 14] . In the present multivariate analysis of patients <40 years, fertility preservation and FIGO stage remained independent prognostic factors for recurrence, seemingly explaining the significantly higher recurrence rates with 19.0% in younger patients compared with 10.1% for patients ≥40 years. Of note, relapses of younger patients presented in 80% as BOT potentially cured by single secondary surgery with again a favourable prognosis [9] . We observed that these recurrences were mostly diagnosed in remaining ovarian tissue without an elevated risk of malignant transformation. Following organ-preserving approach, relapses were diagnosed as BOT in both the ipsilateral remaining ovarian tissue and the contralateral ovary but not as invasive carcinoma.
In contrast, two thirds of patients ≥40 years experiencing recurrent disease were diagnosed with invasive carcinoma and a consecutively impaired prognosis. Almost all of these 16 patients had relapse in form of peritoneal or distant tumour manifestations although initial FIGO stage was lower compared with younger patients. It can be speculated that biological factors influence the clinical course of BOT patients leading to different tumour biology in older patients with recurrent BOT. So far, mutation analyses have shown that both serous BOT and low-grade serous carcinoma may exhibit mutations in KRAS, BRAF and ERBB2 supporting the stepwise pathway from BOT to low-grade carcinoma [15] [16] [17] . In general, mutations in oncogenes have been observed to appear more frequently over lifespan [18] , but it has to be suspected that further intra-cellular processes and changed transduction pathways are responsible for the different behaviour of recurrent BOT in older patients [19] . This is further supported by the fact that half of the patients ≥40 years with recurrent disease were diagnosed with high-grade ovarian carcinoma which is in conflict with the stepwise progression model of ovarian tumour development original articles Annals of Oncology [17, 20] and warrants future investigations. In these cases, a second primary tumour cannot be ruled out since high-grade serous carcinomas tend to develop de novo and not stepwise with an intermediate borderline lesion [21] . Since all cases were subject to reference pathology, the risk of missed primary diagnosis of cancer as described previously should be of low impact in the current study [22] . Nevertheless, patients were retrospectively included and not randomly assigned to one or another treatment strategy, so that the results have to be cautiously interpreted to avoid possible selection bias. However, the AGO ROBOT dataset represents a very large and in detail documented cohort of 950 BOT patients. The participating centres included all consecutive patients during the study period, and all cases were subject to central pathological review leading to a homogenous well-characterized cohort of BOT patients.
The observed age-specific risk of malignant transformation for BOT patients in case of recurrent disease in this study provides evidence to justify fertility-sparing surgery for patients with childbearing potential. Tumour biological mechanisms, reproductive outcome and the role of completion surgery, however, should now be systematically assessed to further substantiate treatment recommendations.
